AbbVie
ABBV
3,386 hedge funds and large institutions have $228B invested in AbbVie in 2024 Q1 according to their latest regulatory filings, with 221 funds opening new positions, 1,337 increasing their positions, 1,494 reducing their positions, and 113 closing their positions.
96% more first-time investments, than exits
New positions opened: 221 | Existing positions closed: 113
29% more call options, than puts
Call options by funds: $3.29B | Put options by funds: $2.55B
18% more capital invested
Capital invested by funds: $193B → $228B (+$35.7B)
10% more funds holding in top 10
Funds holding in top 10: 202 → 223 (+21)
2% more funds holding
Funds holding: 3,327 → 3,386 (+59)
0.66% more ownership
Funds ownership: 70.46% → 71.12% (+0.66%)
11% less repeat investments, than reductions
Existing positions increased: 1,337 | Existing positions reduced: 1,494
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.72B |
| 2 |
Franklin Resources
San Mateo,
California
|
+$616M |
| 3 |
Capital World Investors
Los Angeles,
California
|
+$538M |
| 4 |
Capital International Investors
Los Angeles,
California
|
+$536M |
| 5 |
DZ Bank
Frankfurt Am Main,
Germany
|
+$397M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Pacer Advisors
Malvern,
Pennsylvania
|
-$423M |
| 2 |
Bank of New York Mellon
New York
|
-$391M |
| 3 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$315M |
| 4 |
Charles Schwab
San Francisco,
California
|
-$299M |
| 5 |
Goldman Sachs
New York
|
-$299M |
ABBV Hedge Fund Activity: Q1 2024 in Review
3,386 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in AbbVie (ABBV) for Q1 2024, worth a combined $228B — up 18% from $193B a quarter earlier.
Buyers outnumbered sellers: 221 funds opened new ABBV positions and 113 closed out — a net gain of 108 holders — while 1,337 added to existing stakes and 1,494 trimmed.
The largest buyer was Vanguard Group, adding an estimated $1.72B. The largest seller was Pacer Advisors, cutting an estimated $423M.
- 3,386 institutional investors held AbbVie (ABBV) as of Q1 2024, up from 3,327 in Q4 2023.
- Funds reported $228B of AbbVie stock for Q1 2024, up 18% quarter-over-quarter.
- 221 funds opened new AbbVie positions in Q1 2024 and 113 closed out, a net change of +108 holders.
- The largest AbbVie buyer in Q1 2024 was Vanguard Group, an estimated $1.72B added.
- The largest AbbVie seller in Q1 2024 was Pacer Advisors, an estimated $423M sold.
Based on aggregated 13F filings for Q1 2024.